Technical Analysis for KOD - Kodiak Sciences Inc

Grade Last Price % Change Price Change
B 3.84 1.05% 0.04
KOD closed up 1.05 percent on Friday, November 1, 2024, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 12
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Wide Bands Range Expansion 1.05%
Overbought Stochastic Strength 1.05%
Pocket Pivot Bullish Swing Setup -2.78%
Wide Bands Range Expansion -2.78%
Overbought Stochastic Strength -2.78%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
Gap Up Closed about 22 hours ago
Gap Up Partially Closed about 22 hours ago
Up 3% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kodiak Sciences Inc Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Inflammation Ophthalmology Macular Degeneration Vascular Disease Diabetic Retinopathy Retina Wet Age Related Macular Degeneration Preclinical Stage Product Retinopathy Angiology Retinal Diseases Angiogenesis Retinal Disease Vascular Endothelial Growth Factor

Is KOD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.77
52 Week Low 1.59
Average Volume 203,574
200-Day Moving Average 3.61
50-Day Moving Average 2.88
20-Day Moving Average 3.32
10-Day Moving Average 3.73
Average True Range 0.23
RSI (14) 70.67
ADX 39.07
+DI 30.17
-DI 9.62
Chandelier Exit (Long, 3 ATRs) 3.41
Chandelier Exit (Short, 3 ATRs) 3.20
Upper Bollinger Bands 4.27
Lower Bollinger Band 2.38
Percent B (%b) 0.77
BandWidth 56.99
MACD Line 0.31
MACD Signal Line 0.27
MACD Histogram 0.0415
Fundamentals Value
Market Cap 201.49 Million
Num Shares 52.5 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -0.74
Price-to-Sales 0.00
Price-to-Book 0.93
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.07
Resistance 3 (R3) 4.07 4.01 4.03
Resistance 2 (R2) 4.01 3.95 4.00 4.01
Resistance 1 (R1) 3.92 3.91 3.89 3.92 4.00
Pivot Point 3.86 3.86 3.84 3.85 3.86
Support 1 (S1) 3.77 3.80 3.74 3.77 3.68
Support 2 (S2) 3.71 3.76 3.70 3.67
Support 3 (S3) 3.62 3.71 3.65
Support 4 (S4) 3.62